How to Fairly Allocate Scarce COVID-19 Therapies

Authors

Govind C. Persad, University of DenverFollow
Monica E. Peek, University of Chicago
Seema K. Shah

Publication Date

1-31-2022

Document Type

Article

Organizational Units

Sturm College of Law

Keywords

COVID, Public health, Bioethics, Monoclonal antibodies

Abstract

Vaccines are no longer our only medical intervention for preventing severe COVID-19. Over the past few months, we have seen the arrival and wider availability of treatments such as monoclonal antibodies (mAbs), and more recently, of novel oral antiviral drugs like Paxlovid and molnupiravir. The recent Delta and Omicron surges have made these therapies scarce.

Copyright Statement / License for Reuse

All Rights Reserved.

Publication Statement

User is responsible for all copyright compliance.

Recommended Citation

Govind Persad, Monica Peek & Seema Shah, How to Fairly Allocate Scarce COVID-19 Therapies, Bill of Health (Jan. 31, 2022), https://blog.petrieflom.law.harvard.edu/2022/01/31/how-to-fairly-allocate-scarce-covid-19-therapies/.